Blue Jet Healthcare Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/akjvkaq1wexo2bzpstyjv0fn.pdf

Key Takeaways


Artificial Sweetener: The Quarter's Drag

Ganesh Karuppannan: "The imported material pricing is cheaper. We are not interested in dropping the prices. We don't want to compromise on the gross margin at this stage."

Contrast Media: The Growth Engine

Shiven Arora: "Injectables, as you are aware, have a very strict regulatory control. So even at the intermediate stage, product validation takes years."

Pharma Intermediates: Cardiac Drug Ramps Up


Fire Incident at Mahad: Operational and Financial Impact

Shiven Arora: "It is indeed a heart-wrenching that... we are fully cooperating with the concerned authorities related to the investigations associated with this fire and have put in a mechanism so that we can avoid such incidents to the extent possible."

Capacity, Capex, and the Pipeline


Margins and Cost Structure

Ganesh Karuppannan: "If you look at the high margin period, I think that was because of the COVID impact. I think when COVID started, most of the chemical prices crashed. Especially some of the key raw materials we were importing, the prices literally crashed. So, you have to take it as one outlier."

Guidance & Commitments

CommitmentSpecificsTimeline
Artificial sweetener recoveryCatch up from Q2 shortfallQ4 FY24
Contrast media growthPositive growth for the full financial year based on pipelineFY24
New contrast media launchesA few launches plannedQ4 FY24 to Q1 FY25
Capacity expansionAdd 50% to reach 1,500 KLNext 18 months
Gross margin on existing portfolioReach 57-58% on a sustainable basisNot specified
Gross margin on incremental businessIn excess of 50% to 55%Not specified
Employee cost rangeAround 6-7%, not beyond 7-8%Ongoing
FY24 capexAnother INR 200 croresFY24
FY25 capexAnother INR 150 crores for Unit IV greenfieldFY25
Cardiac esperon capacityNew capacity at Unit II on stream by the time volumes ramp upAligned with customer ramp
New contrast media validation commercializationStart commercializingFY24
Fire de-risking planPresent alternatives to de-risk operationsSubsequent quarter

Key Metrics

MetricQ2 FY24
RevenueDown 4.7% YoY, owing to de-growth in artificial sweetener
EBITDA₹62.6 cr, up 6.7% YoY vs ₹58.7 cr in Q2 FY23
EBITDA margin34.5%, vs 30.9% in Q2 FY23
PAT₹47.9 cr, up 8.9% YoY vs Q2 FY23
PAT margin26.4%, vs 23.1% in Q2 FY23
H1 FY24 revenue growthUp 28.1% YoY vs H1 FY23
H1 FY24 PAT margin25.5%, vs 21.5% in H1 FY23
H1 FY24 gross margin56%–57%
Employee cost~7% of sales, expected to remain in similar range
Capacity utilization~70%
CapacityA little more than 1,000 KL, adding 50% in next 18 months to reach 1,500 KL
H1 FY24 capex₹80 cr
FY24 capex planAnother ₹200 cr in next 6 to 9 months
FY25 capex planAnother ₹150 cr, more on greenfield Unit IV
Saccharine capacity3,500–4,000 metric tons, ~10% of world capacity